Ilumya, Ilumetri(tildrakizumab)
Ilumetri, Ilumya (tildrakizumab) is an antibody pharmaceutical. Tildrakizumab was first approved as Ilumya on 2018-03-20. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Ilumya
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tildrakizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Ilumya | tildrakizumab-asmn | Sun Pharmaceutical Industries | N-761067 RX | 2018-03-20 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ilumya | Biologic Licensing Application | 2025-02-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J3245 | Injection, tildrakizumab, 1 mg |
Clinical
Clinical Trials
42 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 2 | 7 | 11 | 11 | 30 |
| Skin diseases | D012871 | — | L00-L99 | 1 | — | — | 2 | — | 3 |
| Papulosquamous skin diseases | D017444 | — | L40-L45 | — | — | — | 1 | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | 1 | — | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 2 | 4 | — | 2 | 7 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | — | 2 | 3 | — | 2 | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 1 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | — | — | 1 |
| Spondylarthritis | D025241 | — | — | — | 1 | — | — | — | 1 |
| Spondylitis | D013166 | — | M46.9 | — | 1 | — | — | — | 1 |
| Non-radiographic axial spondyloarthritis | D000089202 | — | M45.A | — | 1 | — | — | — | 1 |
| Axial spondyloarthritis | D000089183 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bullous pemphigoid | D010391 | EFO_0007187 | L12 | 1 | — | — | — | — | 1 |
| Vitiligo | D014820 | EFO_0004208 | L80 | 1 | — | — | — | — | 1 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | 1 | — | — | — | — | 1 |
| Skin and connective tissue diseases | D017437 | — | — | 1 | — | — | — | — | 1 |
| Pigmentation disorders | D010859 | — | L81.9 | 1 | — | — | — | — | 1 |
| Hypopigmentation | D017496 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy rate | D018873 | — | — | — | — | — | — | 1 | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Eczema | D004485 | — | L30.9 | — | — | — | — | 1 | 1 |
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | — | — | — | 1 | 1 |
| Pruritus | D011537 | — | L29 | — | — | — | — | 1 | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | — | — | — | — | 1 | 1 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | — | — | — | — | 1 | 1 |
| Abscess | D000038 | EFO_0003030 | — | — | — | — | — | 1 | 1 |
| Chronic urticaria | D000080223 | — | L50.8 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tildrakizumab |
| INN | tildrakizumab |
| Description | Tildrakizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108681 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14004 |
| UNII ID | DEW6X41BEK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,645 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,210 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use